# Phase 1/2 Study Evaluating Safety and Potential Efficacy of Allocetra-OTS Via Pressurized Intra-Peritoneal Aerosol Chemotherapy as Add-on to Standard of Care Chemotherapy for Treatment of Peritoneal Metastasis

> **NCT05431907** · PHASE1,PHASE2 · TERMINATED · sponsor: **Enlivex Therapeutics RDO Ltd.** · enrollment: 9 (actual)

## Conditions studied

- Peritoneal Metastases

## Interventions

- **DRUG:** Allocetra-OTS

## Key facts

- **NCT ID:** NCT05431907
- **Lead sponsor:** Enlivex Therapeutics RDO Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-06-29
- **Primary completion:** 2024-03-14
- **Final completion:** 2024-03-14
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2024-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05431907

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05431907, "Phase 1/2 Study Evaluating Safety and Potential Efficacy of Allocetra-OTS Via Pressurized Intra-Peritoneal Aerosol Chemotherapy as Add-on to Standard of Care Chemotherapy for Treatment of Peritoneal Metastasis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05431907. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*